The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Liposomal Drug Product Development and Quality: Current US Experience and Perspective
Abstract
Research in the area of liposomes has grown substantially in the past few decades. Liposomes are lipid bilayer structures that can incorporate drug substances to modify the drug's pharmacokinetic profile thereby improving drug delivery. The agency has received over 400 liposomal drug product submissions (excluding combination therapies), and there are currently eight approved liposomal drug products on the US market. In order to identify the pain points in development and manufacturing of liposomal drug products, a retrospective analysis was performed from a quality perspective on submissions for new and generic liposomal drug products. General analysis on liposomal drug product submissions was also performed. Results indicated that 96% of the submissions were Investigational New Drug (IND) applications, 3% were New Drug Applications (NDAs), and the remaining 1% was Abbreviated New Drug Applications (ANDAs). Doxorubicin hydrochloride was the most commonly used drug substance incorporated into the liposomes (31%). The majority of the liposomal products were administered via intravenous route (84%) with cancer (various types) being the most common indication (63%). From a quality perspective, major challenges during the development of liposomal drug products included identification and (appropriate) characterization of critical quality attributes of liposomal drug products and suitable control strategies during product development. By focusing on these areas, a faster and more…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, a wide variety of evidence is needed to show equivalence which includes long term clinical monitoring and extensive PK data [288, 293–295].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [294]
In the citing paper
“That is, there is not a distinct or definitive set of critical quality attributes (CQAs), which can accurately predict the in vivo similarity of two distinct nano-based pharmaceuticals or biologic products.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [294]
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 3×
“somes is done using chemical gradient or by other means (23,27,28).”
BackgroundMethodLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
A review on phospholipids and their main applications in drug delivery systems
Li, J., Wang, X., Zhang, T., Wang, C., Huang, Z., Luo, X., & Deng, Y. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.09.004 · Cited by 1,003
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 814
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
An overview of liposome lyophilization and its future potential
Chen, C., Han, D., Cai, C., & Tang, X. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.024 · Cited by 545
Liposome Technology for Industrial Purposes
Wagner, A., & Vorauer-Uhl, K. (2011) · Journal of Drug Delivery · doi:10.1155/2011/591325 · Cited by 435
Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation
Jaafar-Maalej, C., Diab, R., Andrieu, V., Elaissari, A., & Fessi, H. (2010) · Journal of Liposome Research · doi:10.3109/08982100903347923 · Cited by 365
Gubernator, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.566552 · Cited by 325
Intracellular Delivery of Proteins with a New Lipid-mediated Delivery System
Zelphati, O., Wang, Y., Kitada, S., Reed, J. C., Felgner, P. L., & Corbeil, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104920200 · Cited by 214
Research works printed but not linked: 8
- Pharmaceutical Development Q8(R2). International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf . (2009). Accessed 04 Jun 2016.
- Srinivasan A, Iser R. FDA perspectives: common deficiencies in Abbreviated New Drug Applications: part 1: drug substance. Pharm Technol. 2010;34(1):50–9.
- Srinivasan A, Iser R. FDA perspectives: common deficiences in Abbreviated New Drug Applications (part 4). Pharm Technol. 2011;35(4):62–8.
- Srinivasan A, Iser R, Gill DS. FDA perspectives: common deficiencies in Abbreviated New Drug Applications: part 2: description, composition, and excipients. Pharm Technol. 2010;34(8):45–51.
- Srinivasan A, Iser R, Gill DS. FDA perspectives: common deficiencies in Abbreviated New Drug Applications: part 3-control of the drug product and stability. Pharm Technol. 2011;35(2):58–67.
- Impurities in New Drug Products Q3B (R2). International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf . (2006). Accessed 04 Jan 2017.
- Pharmaceutical Quality System Q10. International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf . (2008). Accessed 14 Jun 2016.
- Quality Risk Management Q9. International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf . (2005). Accessed 10 Aug 2016.
Cited by
Liu, P., Chen, G., & Zhang, J. (2022) · Molecules · doi:10.3390/molecules27041372 · Cited by 1,334
“patents and publications are shown in Figure 3 [79].”
BackgroundDesign of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Adapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663
Analytical characterization of liposomes and other lipid nanoparticles for drug delivery
Fan, Y., Marioli, M., & Zhang, K. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113642 · Cited by 395
Metadata
- Authors
- Kapoor, M., Lee, S. L., & Tyner, K. M.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Tyner, Katherine M.
- ORCID
- Tyner, Katherine M.
- Venue
- The AAPS Journal
- Published
- 2017-02-03
- Volume
- 19
- Issue
- 3
- Pages
- 632-641
- ISSN
- 1550-7416 (ISSN-L)
- OpenAlex
- W2584301648
- Cited by
- 116
- References
- 32
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 19 · 2023: 9 · 2022: 12 · 2021: 11 · 2020: 16 · 2019: 11 · 2018: 5 · 2017: 5
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The AAPS Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- pharmaceutical product development, drug quality, critical quality attributes, pharmaceutical manufacturing, regulatory submissions, Investigational New Drug application, new drug applications, abbreviated new drug application, doxorubicin hydrochloride, intravenous administration
- MeSH terms
- Drug Carriers, Drug Industry, Liposomes, Quality Control, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liposomal Drug Product Development and Quality: Current US Experience and Perspective. https://app.cochat.ai/papers/10.1208/s12248-017-0049-9
- The paper
- Kapoor, M., Lee, S. L., & Tyner, K. M. (2017). Liposomal Drug Product Development and Quality: Current US Experience and Perspective. The AAPS Journal. https://doi.org/10.1208/s12248-017-0049-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.